Table 2. Effects of antibiotic exposure on increased 5-year GVHD-related mortality.

PO, per os; IV, intravenous.

AntibioticUntreated 5-year
GVHD-related
mortality (n)
Treated 5-year
GVHD-related
mortality (n)
P
value
Atovaquone (PO)14.1% (772)19.1% (85)0.496
Aztreonam (IV)14.2% (793)17.5% (64)0.777
Cefepime (IV)14.6% (705)13.8% (152)0.980
Ciprofloxacin (IV)14.4% (535)14.7% (322)0.862
Imipenem-cilastatin
(IV)
13.1% (709)21.5% (148)0.025
Metronidazole (IV)14.0% (779)18.6% (78)0.197
Metronidazole (PO)14.0% (801)20.8% (56)0.206
Piperacillin-
tazobactam (IV)
11.9% (557)19.8% (300)0.007
Sulfamethoxazole-
trimethoprim (IV)
14.8% (769)12.9% (88)0.625
Sulfamethoxazole-
trimethoprim (PO)
14.6% (727)12.8% (130)0.522
Vancomycin (IV)13.4% (408)15.6% (449)0.579
Vancomycin (PO)14.4% (796)17.3% (61)0.942